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First-episode schizophrenia (FES) spectrum disorders are
associated with pronounced cognitive dysfunction across all
domains. However, less is known about the course of cognitive
functioning, following the first presentation of psychosis, and
the relationship of cognition to clinical course during initial
treatment. The present longitudinal study examined the magnitude of neurocognitive impairment, using the MATRICS
Consensus Cognitive Battery, in patients experiencing their
first episode of psychosis at baseline and after 12 weeks of
randomized antipsychotic treatment with either aripiprazole
or risperidone. At baseline, FES patients evidenced marked
impairments in cognitive functioning. Notably, performance
on the mazes task of planning and reasoning significantly
predicted the likelihood of meeting stringent criteria for
positive symptom remission during the first 12 weeks of the
trial. Performance on indices of general cognitive function,
working memory, and verbal learning improved over time,
but these improvements were mediated by improvements in
both positive and negative symptoms. We did not detect any
differential effects of antipsychotic medication assignment
(aripiprazole vs risperidone) on cognitive functioning. Our
results suggest that a brief paper-and-pencil measure reflecting planning/reasoning abilities may index responsivity to
antipsychotic medication. However, improvements in cognitive functioning over time were related to clinical symptom
improvement, reflecting “pseudospecificity.”
Key words: cognition/general cognitive function/
psychosis/planning/aripiprazole/risperidone

Introduction
In recent years, cognitive dysfunction has increasingly
been considered a core feature of schizophrenia and
related psychotic disorders.1–3 Moderate deficits are
observed years before the onset of full psychotic symptoms, escalating in severity during adolescence.4,5 By
the onset of psychosis, deficits are nearly as severe as
those observed in patients with chronic illness; studies of patients in the first episode of illness consistently
demonstrate a generalized deficit of 1 SD or more below
the mean performance of healthy individuals.6–8 While
the presence of severe cognitive deficits in first-episode
schizophrenia (FES) spectrum disorders is well established, the relationship between these deficits and early
treatment course remains unclear. Most of the studies
reviewed in recent meta-analyses of FES patients utilized
a cross-sectional design.7,8 Moreover, many of these studies examined patients after clinical stabilization, several
months after initiation of antipsychotic treatment.
Due to the relative difficulty in conducting large-scale,
controlled treatment trials, only a few prospective studies have examined the course of cognitive deficits in FES
patients undergoing initial treatment with antipsychotic
medications. Consequently, several critical questions
remain unresolved. First, it is unclear to what extent cognitive performance at baseline can predict clinical response to
antipsychotic medication. Approximately 40% of patients
will fail to respond to the initial antipsychotic trial9 (see also
Robinson et al,10 this issue), and prognostic biomarkers are
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lacking. In treatment of chronic schizophrenia, the risk of
nonresponse can often be detected within the first 2 weeks
of treatment,11 but early nonresponse is not prognostic
for FES patients.12 Baseline predictive indicators can help
explicate the neurobiology of antipsychotic response and,
ideally, could guide deployment of clinical resources, given
that clinical nonresponse accounts for the large majority
of total health resource utilization associated with psychosis.13 The Center for Intervention Development and
Advanced Research (CIDAR) at the Zucker Hillside
Hospital (ZHH; Malhotra,14 this issue) was designed with
the primary aim of identifying biomarkers that can predict
and explain the heterogeneity of response to antipsychotic
treatment in FES.
A second unresolved question is the degree to which
antipsychotic medication can ameliorate cognitive deficits in FES. The first prospective studies examining cognitive performance before and after 12 weeks of exposure
to initial treatment demonstrated modest improvements
(effect sizes between 0.2 and 0.4 SDs) across most cognitive domains.15–17 However, a comparison with healthy
controls assessed across the same two time-points indicated that practice effects likely accounted for nearly all of
the gains.18 The MATRICS Consensus Cognitive Battery
(MCCB) was specifically designed with alternate forms to
minimize practice effects for use in controlled treatment
trials,19 but to date it has never been examined in an acute
trial of FES patients; the present study is the first to do so.
Moreover, the extent to which cognitive improvement after treatment may be secondary to clinical
changes (reduction of positive and/or negative symptoms) remains an open question. While studies in chronic
patients typically demonstrate modest but significant
correlations between cognition and clinical symptomatology (both cross-sectionally and over time20), prior
studies in FES patients have yielded mixed results. Some
studies have suggested that correlations between cognitive improvement and symptom reduction were specific
to first-generation antipsychotics only,16,17 while others
have demonstrated broad correlations between cognitive
and clinical change.21 Moreover, cross-sectional and longitudinal studies in FES patients have consistently demonstrated correlations of cognitive deficits with negative
symptoms.6,22–24
Finally, while studies of cognitive effects have typically
demonstrated broad similarities across various secondgeneration antipsychotic agents,15,21 aripiprazole has
not yet been well studied. Only one comparative study
has been conducted in a FES cohort; in an unblinded
6-month trial conducted in China, aripiprazole demonstrated broadly similar effects to risperidone, except for
a failure to enhance processing speed.25 By contrast, in
a comparison of 4 second-generation antipsychotics in
a (mostly) chronic cohort, Riedel et al26 reported that
aripiprazole demonstrated the greatest ability to improve
reaction time and attention. Two other studies in chronic
1238

patients27,28 have suggested that aripiprazole may have distinctive cognitive properties (both positive and negative)
as a result of its unique mechanism of action (partial agonism rather than pure antagonism at the dopamine D2
receptor). Moreover, aripiprazole (but not risperidone)
has demonstrated modestly beneficial effects on negative
symptoms (Robinson et al,10 this issue), which may be
critical to cognitive change.29 Thus, it is plausible that differential cognitive effects of aripiprazole vs risperidone
may also be observed.
The present study was, therefore, designed to prospectively test several unanswered questions in the treatment
of FES: (1) Can baseline cognitive measures predict clinical response to antipsychotics?; (2) Can antipsychotic
medications ameliorate cognitive deficits in first-episode
patients, independent of practice effects and clinical
changes?; and (3) Are there differences in the cognitive
effects of aripiprazole vs risperidone? As noted above, the
present study utilized the MCCB, which is designed to
reliably and efficiently assess each of 7 dissociable cognitive factors that have been replicably identified in the
schizophrenia literature.30 These questions were addressed
in the context of a 12-week, blinded controlled study of
aripiprazole vs risperidone, as described in greater detail
elsewhere in this volume.10
Methods
Full methodological details regarding the 12-week randomized clinical trial can be found in the accompanying
manuscript by Ref: 10. Details of the ZHH CIDAR initiative that are principally relevant to the current study are
described below.
Participants
Table 1 provides demographic information about the
sample. The current study included 175 participants (73%
male; mean age of 22.55 ± 5.67 y) at study entry with a
schizophrenia spectrum disorder (schizophrenia, n = 123
[67%]; schizophreniform disorder, n = 35 [23%]; schizoaffective disorder, n = 5 [3%]; or psychotic disorder not otherwise specified, n = 12 [7%]). Participants were recruited
from a consortium of 10 collaborative medical centers
including 8 in the greater New York City area, as well as
San Antonio, Texas and Calgary, Alberta, Canada. The
sample was racially/ethnically and socioeconomically
diverse, as study sites were located in urban or suburban
areas and served diverse communities. Study data were
collected from December of 2005 through April of 2013.
Study inclusion and exclusion criteria are summarized in
supplementary table 1. Inclusion criteria required all participants to have less than 2 weeks of prior antipsychotic
exposure and 28% of our sample (n = 49) was completely
antipsychotic medication naive. Any antipsychotics
being taken at the time of study entry were discontinued and participants started randomized medication

Cognitive Function in First-Episode Psychosis

Table 1. Demographic and Clinical Characteristics of Full Sample (N = 175) at Baseline, and Those Who Did (N = 109) and Did Not
(N = 66) Complete the NP Evaluation at Both Time Points

Male
Racial/ethnic minority
Randomized to aripiprazole
Randomized to risperidone

Age (y)
Paternal education
Paternal Hollingshead social class
Maternal education
Maternal Hollingshead social class
WRAT-3 estimated premorbid IQ
MCCB general composite, baseline
Handedness (percent right-handed)
BPRS Positive symptoms
SANS Affective flattening
SANS Alogia
SANS Avolition
SANS Anhedonia

Full Sample

Completed
Full NP

Did Not
Complete NP

N = 175

N = 109

N = 66

N

%

N

%

N

%

P

128
135
93
82

73.14
77.14
53.14
46.86

82
84
60
49

0.75
0.77
0.55
0.45

46
51
33
33

0.70
0.77
0.50
0.50

.424
.975

Mean

SD

Mean

SD

Mean

SD

22.55
13.18
3.92
12.95
3.78
97.07
33.52
0.89
14.55
1.80
2.03
2.08
2.13

5.67
3.34
1.71
2.97
2.02
12.41
9.36
0.32
3.59
0.97
1.06
1.03
0.97

22.10
12.69
3.99
12.72
3.90
95.79
33.70
0.85
14.48
1.92
2.08
2.21
2.15

5.40
3.44
1.63
3.08
2.08
12.99
9.62
0.36
3.35
1.02
1.08
1.07
0.98

23.29
14.31
3.76
13.46
3.54
99.13
33.22
0.95
14.67
1.62
1.94
1.88
2.11

6.07
2.81
1.90
2.69
1.89
11.21
9.01
0.21
3.97
0.84
1.04
0.92
0.95

.517

.179
.014
.506
.186
.363
.127
.749
.093
.742
.050
.387
.041
.782

Note: BPRS, Brief Psychiatric Rating Scale; MCCB, MATRICS Consensus Cognitive Battery; NP, neuropsychological; SANS, Scale for
the Assessment of Negative Symptoms; WRAT-3, Wide-Range Achievement Test, 3rd edition.

without a withdrawal period. After complete description of the study, written informed consent was obtained
from all adult participants. For participants younger than
18 years, written parental consent and written participant
assent were obtained. The study was conducted under the
auspices of the Feinstein Institute for Medical Research
Institutional Review Board (IRB) as the coordinating
center and the IRBs of the clinical sites.
Clinical Assessment Measures
Initial diagnosis for eligibility was established with
the Structured Clinical Interview of Axis I DSM-IV
Disorders (SCID).31 These data were later reviewed in a
consensus conference for final diagnostic assignment.32
Assessments done at baseline, weekly for 4 weeks, and
then every 2 weeks included: Brief Psychiatric Rating
Scale-Anchored version (BPRS-A)33; Hillside clinical trials version of the Schedule for Assessment of Negative
Symptoms (SANS)34; and the Clinical Global Impression
Scale (CGI).35
Treatment Protocol
The acute treatment study phase lasted 12 weeks
(85.2 ± 5.7 d elapsed from baseline to follow-up on average). Participants were stratified by site, previous antipsychotic exposure (none vs any), and diagnosis (psychotic

disorder Not Otherwise Specified vs other eligible diagnoses) and were randomly assigned on a 1:1 basis to doublemasked treatment with either aripiprazole (5–30 mg/d) or
risperidone (1–6 mg/d).
Antipsychotic Treatment Response Criteria
Response to antipsychotic treatment was based on a
priori criteria that was defined as follows: (1) a rating
of 3 (“mild”) or less on all of the following items of the
BPRS-A: conceptual disorganization, grandiosity, hallucinatory behavior, unusual thought content and (2) a CGI
Improvement rating of “much improved” or “very much
improved.” These criteria were required to be sustained
on 2 consecutive rating assessments for a patient to be
considered as a responder. Time of response was the date
of the first of the 2 consecutive ratings meeting these
criteria.
Cognitive Evaluation With the MCCB
The MCCB is a battery of neuropsychological tests that
were rigorously identified for inclusion as a standardized approach to the serial assessment of key cognitive
deficits in medication trials for patients with schizophrenia and related disorders.36 The MCCB includes 7
cognitive domains: Speed of Processing (semantic fluency [animal naming], Brief Assessment of Cognition
1239
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in Schizophrenia [BACS] symbol coding, and part A of
the Trail Making test); Working Memory (letter-number span and spatial span); Reasoning and Problem
Solving (Neuropsychological Assessment Battery [NAB]
Mazes); Verbal Learning (Hopkins Verbal Learning TestRevised [HVLT-R]); Visual Learning (Brief Visuospatial
Memory Test-Revised [BVMT-R]); Attention/Vigilance
(Continuous Performance Test, Identical Pairs [CPT-IP]);
and Social Cognition (Mayer-Salovey-Caruso Emotional
Intelligence Test [MSCEIT], Managing Emotions). In
addition to the 7 domain scores, the MCCB provides
an overall composite score that indexes general cognitive performance across domains. Trained psychometricians administered the battery, and administration of all
MCCB tests adhered to procedures described in the test
manual.36
Statistical Procedures
Quality Control. Raw data for continuous variables
were plotted using standard procedures (eg, histograms
and Q-Q plots) and examined for normality. Extreme
outlier data points (defined as a value whose distance
from the nearest quartile was greater than 1.5 times the
interquartile range in either direction) were removed.37
Cognitive performance data were adjusted for age, sex,
site (using 2 site indicator variables; one representing the
largest site [ZHH] as the reference group and one representing the Calgary site, which had significantly higher
cognitive scores compared to all other sites, as the reference group), and racial/ethnic minority status.
Baseline Cognitive Predictors of Response to
Treatment. Initial analyses compared the rates of antipsychotic treatment response (based on criteria defined
above) over the 12-week trial as a function of cognitive
performance at study entry using the MCCB. These analyses used Cox regression procedures, under a proportional hazards model, to assess clinical response status
and time as a function of baseline cognitive status and
relevant covariates.
Change in Cognitive Performance in Relation to
Antipsychotic Medication and Psychosis Symptomatology.
Next, we examined whether cognitive performance in
FES is: (1) stable, declines, or improves after 3 months
time; (2) dissimilar in trajectory depending on whether
patients were randomized to aripiprazole (a partial
dopamine agonist) vs risperidone (a dopamine antagonist); and (3) mediated by improvements in positive
and negative symptoms (ie, if changes could be due
to “pseudospecificity,” simply reflecting antipsychotic
effects on symptoms). Analyses of longitudinal patterns of change in cognitive performance as a function
of antipsychotic drug and psychosis symptomatology
were carried out using a series of linear mixed-model
1240

approaches in SAS.38 Factors in the models were time,
medication type, time × medication type interaction,
the sum of BPRS remission items, and the 4 global
SANS scores. A random intercept in the mixed models
was used to account for correlation of measurements
over time among the participants; the correlational
type was assumed to be unstructured. The difference in
slopes of the outcomes between the 2 treatment groups
was assessed using a group-by-time interaction term in
the mixed models.
Results
Premorbid IQ estimated from the word reading subtest of
the Wide-Range Achievement Test, 3rd edition (WRAT3) was in the average range (mean = 97.07 ± 12.41), and
participants were predominantly right-handed (89% ±
32%). As shown as part of table 1, 109 of 175 participants completed cognitive evaluations at baseline and
follow-up. Completers and noncompleters were not significantly different in key clinical variables including age,
race/ethnicity, antipsychotic type, IQ, and most symptom
measures, except for affective flatting and avolition, which
were slightly higher in completers. As shown in table 2,
our FES cohort demonstrated marked impairments in
cognitive functioning across domains on the MCCB at
baseline, with an average T score of 33.8 ± 11.8, more than
1.5 SDs below the general population mean. On average,
scores improved slightly from baseline to 3-month follow-up across domains, although performance was still
markedly impaired with an average T score of 35.5 ± 11.1.
Deficits in processing speed were the most pronounced
of all domains, and social cognition was least impaired
relative to the other domains. Table 2 also provides summaries of the raw score data from each individual test
across time.
Baseline Predictors of Response
In Cox regression analyses, after controlling for potential demographic confounds, as well as the sum of BPRS
remission items and SANS negative symptoms at study
entry, general cognitive performance at baseline significantly predicted 12-week response rates to antipsychotic
treatment (Wald statistic = 4.62, P = .032). Further, adding this term significantly improved model fit (χ2 change:
4.73, P = .030). To determine if a specific process drove
the general cognitive effect, subsequent analyses examined the 7 MCCB domains individually for association to
treatment response. After strict Bonferroni correction for
multiple comparisons, baseline performance in the MCCB
reasoning domain (as measured by the NAB mazes subtest) was a significant and robust predictor of response to
antipsychotic treatment (Wald statistic = 10.02, P = .002)
when entered into the model (χ2 change: 9.94, P = .002).
As shown in table 3, in both instances, individuals who
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Table 2. MCCB Standardized Domain Scores and Raw Subtest Scores at Baseline
Baseline

MCCB domain (T scores)
General cognitive function
Speed of processing
Working memory
Reasoning/problem solving
Verbal learning
Visual learning
Attention/vigilance
Social cognition
MCCB subtest (raw scores)
BACS symbol coding
Semantic fluency (animals)
Trails A
Letter-number span
Spatial span
NAB mazes
HVLT-R total score, trials 1–3
BVMT-R total score, trials 1–3
CPT-IP dʹ
MSCEIT managing emotions

Week 12

N

Mean

SD

Min.

172
170
165
164
172
168
125
152

33.39
30.18
32.45
36.85
35.39
32.51
32.12
37.21

9.39
15.05
14.38
10.85
8.79
12.47
10.51
13.07

8.20
−3.00
−10.00
15.00
17.00
−3.00
6.00
4.00

172
172
170
166
170
164
172
168
125
152

44.93
19.09
40.13
11.96
13.68
16.29
20.33
19.80
1.95
84.44

13.71
7.20
19.57
4.38
4.22
6.84
5.74
7.02
0.72
11.47

11.00
3.00
16.72
1.00
3.00
0.00
3.00
0.00
−0.07
54.54

Max.

N

Mean

SD

Min.

Max.

57.00
71.00
63.00
62.00
72.00
61.00
57.00
67.00

109
108
106
105
111
109
88
101

35.49
30.96
37.92
38.75
37.56
33.98
31.85
37.43

8.61
12.25
12.38
10.83
8.94
12.51
11.64
11.99

10.50
−5.00
6.00
16.00
19.00
−1.00
6.00
14.00

58.29
64.00
76.00
63.00
67.00
59.00
62.00
63.00

80.00
38.00
109.12
22.00
25.00
26.00
35.00
35.00
3.64
109.15

111
109
111
107
111
105
111
109
88
101

45.86
18.91
37.01
13.07
15.41
17.69
21.79
20.70
1.95
83.97

11.66
5.76
14.91
3.62
4.01
6.28
5.55
7.07
0.76
10.84

9.00
8.00
15.56
4.00
7.00
0.00
5.00
1.00
0.27
54.58

80.00
41.00
83.65
21.00
28.00
26.00
34.00
35.00
3.94
107.96

Note: Domain scores are presented as T scores (M = 50, SD = 10) and domain subtest scores are presented as raw data scores (eg,
number of seconds to complete Trails A). BACS, Brief Assessment of Cognition in Schizophrenia; BVMT-R, Brief Visuospatial
Memory Test - Revised; CPT-IP, Continuous Performance Test - Identical Pairs; HVLT-R, Hopkins Verbal Learning Test - Revised;
MCCB, MATRICS Consensus Cognitive Battery; NAB, Neuropsychological Assessment Battery; MSCEIT, Mayer-Salovey-Caruso
Emotional Intelligence Test.

evidenced better cognitive functioning in general and specifically in the domain of reasoning at baseline responded
faster to subsequent antipsychotic treatment as compared
to patients who were relatively more impaired.
We then examined the specificity of reasoning relative
to the other cognitive domains. After controlling for age,
sex, minority status, and site on step 1, baseline SANS
negative symptoms on step 2, and the 6 other MCCB
cognitive domains on step 3, adding reasoning on step
4 significantly improved the model fit (χ2 change = 8.03,
P = .005), and reasoning continued to evidence a significant association to treatment response (B = 0.051,
SE = 0.018, Wald = 8.08, P = .004). Thus, reasoning/
problem solving at baseline specifically predicted treatment response, as no other cognitive domains were significant (P > .29; table 3). Further, the association of
general cognitive function to treatment response was primarily driven by reasoning/planning performance on the
mazes task.
To better understand the association between MCCB
reasoning and treatment response, we examined the trajectory of sustained response rates across the 12-week
treatment phase. In order to perform a graphical examination, we classified individuals as high performers on
NAB mazes (defined as those scoring at or above the 75th
percentile within the sample), average performers (those
who scored below the 75th percentile and above the 25th
percentile), and low performers (those who performed at

or below the 25th percentile). As shown in figure 1, only
20% of patients in the low performing group responded
favorably to antipsychotic treatment by the midpoint of
the trial (week 6) compared to 60% of the high performing group. By week 12, 40% of the low group responded
to treatment compared to 80% of patients in the high
group. Response rates for the average/middle group fell
in-between the high and low groups.
Changes in Cognitive Performance
During the 3 months of treatment, general cognitive function improved by approximately 2 points, working memory improved by 5 points, and verbal learning improved
by 2 points. No other MCCB domain evidenced significant change from baseline to follow-up (supplementary
table 2). In the sections below, we report the results of
examining how these changes in cognition were influenced by clinical variables, specifically medication type
and symptom change.
Comparison of Aripiprazole and Risperidone in
Cognitive Performance Change
No differential effects of aripiprazole vs risperidone on
cognitive performance were observed. Specifically, there
were no statistically significant antipsychotic medication
type (aripiprazole vs risperidone) × time interactions for
any cognitive variables (all P > .35).
1241
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Table 3. Baseline Cognitive Predictors of Treatment Response

Block 1

Block 2

Block 3
Block 1

Block 2

Block 3

Block 4

Variable

B

SE

Wald

P value

OR

95% CI lower

95% CI upper

Sex
Age
Minority status
Site indicator 1 (ZHH)
Site indicator 2 (Calgary)
BPRS Positive symptoms
SANS Affective flattening
SANS Alogia
SANS Avolition
SANS Anhedonia
General cognitive function

−0.050
0.311
0.179
−0.028
1.347
−0.048
0.029
0.037
0.058
−0.215
0.03

0.023
0.269
0.294
0.242
0.653
0.036
0.126
0.127
0.147
0.167
0.014

4.807
1.338
0.372
0.013
4.251
1.826
0.054
0.086
0.158
1.66
4.622

.028
.247
.542
.909
.039
.177
.816
.770
.691
.198
.032

0.951
1.365
1.196
0.973
3.844
0.953
1.030
1.038
1.060
0.807
1.03

0.909
0.806
0.673
0.605
1.069
0.889
0.804
0.809
0.795
0.582
1.003

0.995
2.311
2.127
1.563
13.825
1.022
1.318
1.332
1.414
1.119
1.059

Age
Sex
Minority status
Site indicator 1 (ZHH)
Site indicator 2 (Calgary)
BPRS Positive symptoms
SANS Affective flattening
SANS Alogia
SANS Avolition
SANS Anhedonia
Speed of processing
Working memory
Verbal memory
Visual memory
Attention/vigilance
Social cognition
Reasoning/problem solving

−0.064
0.206
0.818
−0.059
1.535
−0.101
−0.037
0.034
0.138
−0.334
0.002
0.018
0.000
0.007
−0.019
−0.013
0.051

0.033
0.370
0.401
0.305
0.706
0.048
0.151
0.172
0.184
0.204
0.016
0.017
0.021
0.020
0.018
0.013
0.018

3.723
0.309
4.166
0.037
4.725
4.477
0.060
0.039
0.562
2.686
0.009
1.038
0.000
0.113
1.079
0.895
8.081

.054
.578
.041
.847
.030
.034
.806
.843
.453
.101
.926
.308
.987
.737
.299
.344
.004

0.938
1.229
2.265
0.943
4.642
0.904
0.964
1.035
1.148
0.716
1.002
1.018
1.000
1.007
0.981
0.987
1.053

0.879
0.595
1.033
0.519
1.163
0.823
0.717
0.739
0.801
0.481
0.970
0.984
0.960
0.968
0.947
0.962
1.016

1.001
2.539
4.968
1.714
18.533
0.993
1.295
1.448
1.645
1.068
1.034
1.053
1.041
1.047
1.017
1.014
1.091

Note: The upper half of the table displays the results of general cognitive function, and the lower half of the table displays the results of
reasoning after controlling for the other 6 cognitive domains. B, regression coefficient. Bold values indicate significant P values for Table
3; BPRS, Brief Psychiatric Rating Scale; SANS, Scale for the Assessment of Negative Symptoms; SE, standard error of B; ZHH, Zucker
Hillside Hospital.

Changes in Cognitive Performance in Relation to
Symptom Improvement
As described above and in supplementary table 2, general
cognitive function, working memory, and verbal learning improved from baseline to 12-week follow-up. To test
whether these improvements were dependent upon reductions in clinical symptomatology, we conducted a series
of mediation analyses. For these analyses, we employed
the causal-steps approach,39,40 which states that 4 steps
in the causal process must be true for full mediation to
be present: (1) The total effect of the predictor on the
outcome must be significant; (2) The effect of the predictor on the mediator must be significant; (3) The effect of
the mediator on the outcome controlling for the predictor must be significant; and (4) The direct effect of the
predictor on the outcome adjusting for the mediator must
be nonsignificant.39,40 We used the BPRS remission items
and SANS global measures of affective flattening, alogia,
avolition-apathy, and asociality-anhedonia as mediating
variables in these models, adding them after we examined
the main, unconditional effect of antipsychotic treatment.
Details of the mediation analysis are provided in figure 1 and supplementary table 3. In all cases, changes in
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cognitive performance were either partially or fully mediated by changes in BPRS remission scores and/or global
alogia as rated on the SANS. Specifically, improvements
in general cognitive functioning were partially mediated
by changes in positive symptoms and fully mediated
by improvements in alogia. Improvements in working
memory were fully mediated by reductions in BPRS
remission scores and partially mediated by reductions in
alogia. Finally, the mediating effect of BPRS remission
scores on improvements in verbal learning was inconclusive because the direct effect of BPRS on verbal
learning controlled for time was not significant; however, improvements in verbal learning were fully mediated by reductions in alogia. These results are displayed
pictorially in figure 2, which show (1) that antipsychotic
medication type had no differential affect on cognition and (2) that the simple slopes of the change from
baseline to follow-up flatten out over time after covarying for clinical improvement. Additional results of this
analysis are presented in supplementary table 4 for the
other cognitive domains. Notably, after controlling for
symptoms, social cognition declined significantly over
time (P = .032).
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Fig. 1. Result of Cox regression analysis of MATRICS Consensus Cognitive Battery reasoning/problem solving performance at baseline
in relation to 12-week treatment response rates. As can be seen, ~50% of the patients who performed relatively well on the task at
baseline (defined as those scoring at or above the >75th percentile within the sample) successfully responded to antipsychotic treatment
after 6 weeks, whereas only ~20% of poor performers (ie, those who performed at or below the 25th percentile) met criteria after the same
period of time.

Discussion
In this study, we examined baseline cognitive predictors
of antipsychotic treatment response in a large sample
of medication-naive or minimally treated FES patients.
We found that better general cognitive functioning at
baseline, which was driven by performance on a test of
planning and reasoning, was associated with a faster rate
of positive symptom response. We also compared the
effectiveness of aripiprazole and risperidone in improving cognitive function, and our results indicate that differential medication effects were not detectable. Lastly,
small but significant improvements in general cognitive
function, working memory, and verbal learning were seen
over time, but these findings were mediated by improvements in clinical symptomatology.
The most striking result of our study was the ability of
baseline cognitive performance, specifically the MCCB
reasoning subtest, to predict 12-week clinical response to
risperidone or aripiprazole. Our clinical response measure was strictly defined as an absence of psychotic-level
positive symptoms observed over 2 consecutive assessments (see Ref: 10, this issue). As demonstrated in figure 1,
patients in the top quartile of scores on MCCB reasoning were twice as likely to respond as those in the bottom quartile. Notably, our results were highly specific to
the reasoning domain score: (1) Similar results were not
observed for other cognitive domains and (2) Multiple
regression demonstrated no attenuation of results for the
reasoning test when all other domain scores were entered

into the model first. This specificity is striking, given that
the large majority of the cognitive variance in schizophrenia is accounted for by generalized, as opposed to
specific, deficits.41,42
While pretreatment cognitive performance has not
been widely studied as a clinically relevant prognostic
biomarker, a few studies have suggested that this may
be a promising avenue for future research. For example,
in an early study of FES patients treated with fluphenazine, we demonstrated that an “attention” domain score
(which included working memory measures as well) significantly predicted positive symptom response within
the first year.43 More recently, a small (n = 28) naturalistic study indicated that first-episode patients with higher
baseline scores on MCCB attention and verbal memory
scales (but not reasoning) were more likely to meet remission criteria after 6 months of treatment.44 Another small
study (n = 55, divided into 3 medication groups) also
found that verbal memory, as well as a novel measure
of planning, predicted acute (8 wk) positive symptom
response.45 Differing sample characteristics and test batteries may account for the failure to converge on a single
prognostic measure, but collectively these studies strongly
suggest that brief paper-and-pencil measures of neurocognitive functioning may provide significant prognostic
information.
Given the relative paucity of functional neuroimaging
studies examining maze performance, which forms the
basis of the MCCB reasoning scale, a neurobiological
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Fig. 2. Results of mediation analysis of clinical symptoms on cognitive change. Improvements in clinical symptoms partially and/or fully
mediated improvements in (a) general cognition, (b) working memory, and (c) verbal learning.

interpretation of this result is not straightforward. To
our knowledge, only 1 neuroimaging study has been conducted using this paradigm; as expected, results demonstrated a robust activation of a dorsal frontoparietal
attention network.46 Notably, the study also found activations of the basal ganglia and cortical motor areas,
despite using a nonmotoric (imaginary performance only)
version of the task. Relatedly, specific deficits in maze
performance were reported in a study of neurological
patients with basal ganglia infarcts.47 Thus, it is possible
that MCCB reasoning performance may serve to index
dopamine-sensitive frontostriatal circuitry relevant to the
mechanism of action of antipsychotic medications. Such
a conclusion is consistent with our recent observation that
frontostriatal connectivity, measured with resting-state
functional magnetic resonance imaging, is a powerful
(sensitivity = 80% and specificity = 75%) and replicable
prognostic biomarker of antipsychotic response in both
first-episode and multiepisode patients.48
As noted, we found changes in general cognition,
working memory, and verbal learning that were highly
significant for a time effect when no symptom covariates were included, but these associations became nonsignificant when time-varying symptom dimensions were
included. In all cases, BPRS remission score and SANS
global alogia were consistently significant in the models,
implicating a mediation effect of these symptoms on cognition.39 However, it should be noted that such “pseudospecificity” (ie, cognitive improvement that could result
from reductions in other aspects of the illness) cannot be
fully explicated with post hoc statistical approaches.49
Although the introduction of second-generation antipsychotics held the promise of nootropic effects, our
longitudinal cognitive data are consistent with a growing
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body of evidence that second-generation antipsychotics
provide no specific cognitive benefit.50 While several cognitive scores improved modestly over the course of our
12-week trial, gains were entirely eliminated when controlling for changes in positive and negative symptoms. These
results are consistent with other recent studies reporting
a significant correlation between cognitive change and
symptom remission in FES patients.21,44,51 Indeed, 1 study
concluded that verbal memory was a state marker of psychosis remission52; our use of a mediation model provides
formal statistical support for this assertion.
Our results do not support a special role for aripiprazole, as compared to other second-generation antipsychotic agents, in the treatment of cognitive deficits.
Despite a putative difference in mechanism of action,
there is no difference in the effects of aripiprazole and
risperidone on cognitive performance, just as there was
no difference in positive symptom response (Ref: 10, this
issue). Differences in negative symptom change and
motoric side effects reported elsewhere in this issue were
not reflected in cognitive scores in any domain.
Several limitations of the present study should be
noted. First, although comparisons between completers
and noncompleters suggested that the 2 groups did not
differ on most clinical and demographic variables, paternal education was higher in noncompleters, and SANS
global affect and avolition were lower in noncompleters.
However, it is unlikely that these results influenced our
findings. Second, we did not include a control group
to examine practice effects. However, the MCCB was
designed to ameliorate this potential confound, and the
fact that no cognitive domain change scores were significant after controlling for symptom change suggests that
practice effects were limited. Nonetheless, it is plausible
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that the extent of overall change in the MCCB reflected
learning/practice effects, and that reduction of psychosis
may permit patients to successfully learn from practice.
In the schizophrenia literature, psychotic symptomatology is not strongly correlated with concurrent measures
of cognitive performance,53 but it may more strongly
interfere with learning ability over time, with significant
implications for cognitive remediation.54 An alternative
interpretation is that the ability to solve problems (as
measured by the mazes subtest of the MCCB) predicts
the ability to learn with practice, which may or may not
be mediated by clinical response. Finally, our mediation
models were not designed to explain the direction of the
cognitive-symptom change interactions, although it is
intuitive that symptom reduction causally preceded cognitive improvement.
Nevertheless, the present results suggest that planning
and reasoning skills in FES might hold prognostic value
in helping to determine which patients are likely to rapidly
benefit from second-generation antipsychotic treatment.
Moreover, severe cognitive deficits remain a substantial
problem in the treatment of FES, and novel pharmacologic
and/or behavioral strategies are needed to ameliorate them.
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Supplementary material is available at http://schizophreniabulletin.oxfordjournals.org.
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